Key Finding
Traditional Chinese Medicine shows promise as adjuvant therapy with PD-1/PD-L1 immune checkpoint inhibitors, potentially enhancing anticancer effects through synergistic mechanisms while addressing limitations of low response rates and adverse events.
This research review explores how Traditional Chinese Medicine (TCM) might enhance modern cancer immunotherapy treatments. Scientists examined PD-1/PD-L1 inhibitors, which are newer cancer drugs that help the immune system recognize and fight tumors by blocking signals that cancer cells use to hide from immune detection. While these medications show promise, they have limitations including low response rates in some patients, side effects, and the development of drug resistance over time.
Researchers found that combining PD-1/PD-L1 blocking drugs with other treatments like surgery, chemotherapy, radiation, and TCM produces better results through synergistic effects. TCM, which includes herbal medicine, acupuncture, and other traditional therapies, appears to support these modern immunotherapy treatments through multiple complex mechanisms. The holistic approach of TCM may help reduce side effects, improve immune function, and enhance overall treatment outcomes when used alongside conventional cancer therapies.
This is important for cancer patients considering complementary approaches because it suggests TCM can play a meaningful supportive role during immunotherapy treatment. The combination approach addresses the body as a whole system rather than targeting only the tumor, which aligns with traditional Chinese medical philosophy. However, the review also notes that more research is needed to fully understand how TCM works with these newer cancer drugs and to establish standardized treatment protocols.
For patients interested in integrating acupuncture or other TCM therapies with cancer treatment, finding a qualified, licensed practitioner with experience in oncology support is essential.
This comprehensive review examines combination strategies involving PD-1/PD-L1 immune checkpoint inhibitors for cancer treatment, with particular emphasis on TCM adjuvant therapy. The authors analyzed how PD-1/PD-L1 blockade reverses immunosuppression by preventing T cell inhibition, cytokine suppression, and reduced cytotoxicity. Key limitations of PD-1/PD-L1 monotherapy identified include low response rates, immune-related adverse events (irAEs), and drug resistance development.
The review found that multi-modal combinations with surgery, chemotherapy, radiotherapy, immunotherapy, hormone therapy, and TCM demonstrate synergistic effects that expand therapeutic potential. TCM's role as adjuvant therapy operates through complex, multi-target mechanisms consistent with its holistic principles. While no specific sample sizes or effect sizes were provided in this theoretical review, the authors emphasize TCM's capacity to modulate immune function, reduce treatment-related toxicity, and potentially overcome resistance mechanisms.
Clinical takeaway: TCM integration with PD-1/PD-L1 immunotherapy represents a promising combination approach for oncology patients, though standardized protocols and additional clinical trials are needed to optimize treatment parameters and validate mechanisms of action.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Acupuncture significantly improved total sleep time by approximately 30 minutes and sleep efficiency by 4.56% compared to control groups in breast cancer patients with systemic therapy-associated insomnia.
📌 Cognitive behavioral therapy and hypnosis have the strongest evidence for reducing vasomotor symptoms in breast cancer survivors, while acupuncture may provide modest benefit as an adjunctive nonpharmacological treatment option.
📌 Traditional acupuncture reduced hot flash and night sweat frequency by nearly 50% in breast cancer survivors taking tamoxifen, with sustained effects lasting at least 18 weeks after treatment ended.